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Diagnosis and Treatment of Burn Wound Infections {#Sec00041}
------------------------------------------------

### Introduction {#Sec00042}

Infections remain a leading cause of death in burn patients. This is as a result of loss of the environmental barrier function of the skin predisposing these patients to microbial colonization leading to invasion. Therefore, reconstitution of the environmental barrier by debriding the devitalized tissue and wound closure with application of allograft versus autograft is of optimal importance.

Given that infections are a common complication of the thermally injured patient, early diagnosis and treatment are of paramount importance. The pathophysiological progression of burn wound infection runs the spectrum from bacterial wound colonization to infection to invasive wound infection. The characteristics of each are as follows: *Bacterial colonization* Bacterial levels \<10^5^Does not necessarily prevent wound healing*Bacterial infection* Bacterial levels \>10^5^Can result in impaired wound healing and graft failureCan lead to systemic infection*Invasive wound infection* Clinically can have separation of the eschar from wound bedAppearance of focal dark brown, black, or violaceous discoloration of the wound \[[@CR00041]\]Presence of pyocyanin (green pigment) in subcutaneous fatErythema, edema, pain, and warmth of the surrounding skinAssociated with signs of systemic infection/sepsis and positive blood cultures

Of note there are particular clinical signs unique to fungal and viral infections. An unexpected and rapid separation of the eschar is characteristic of fungal infection \[[@CR00042]\], while vesicular lesions caused by HSV-1 can be found in healed or healing burn wounds \[[@CR00043]\].

### Common Pathogens and Diagnosis {#Sec00043}

In general the organisms causing burn wound infection/invasion have a chronological appearance. Initially, Gram-positive organisms are commonplace, while Gram-negative organisms become predominant after 5 days post-burn injury. Yeast and fungal colonization/infection follow, and finally multiresistant organisms appear typically as result of broad-spectrum antibiotics or inadequate burn excision or patient response to therapy \[[@CR00044]\].

As part of infection surveillance of burn patients, clinicians need to pay close attention to clinical signs of wound infection and rapidly confirm their diagnosis. There is some controversy as to the exact method of diagnosis, with some advocating for quantitative cultures---with \>10^5^ organisms per gram tissue being diagnostic of invasive infection \[[@CR00045]\]---and others arguing for histological examination as the only reliable method of determining invasive infection \[[@CR00046]--[@CR00049]\] since quantitative cultures are only positive in 50 % of histological invasive wound infections \[[@CR00049]\]. The most common pathogens of burn wound invasion are MSSA, MRSA, and *Pseudomonas aeruginosa* species (Table [4.1](#Tab00041){ref-type="table"}).Table 4.1Common pathogens of burn wound infectionOrganismCommon speciesGram-positive bacteria*Staph* and *Strep* speciesGram-negative bacteria*Pseudomonas aeruginosa, Acinetobacter baumannii, E. coli, Klebsiella pneumoniae, Enterobacter cloacae*Yeast*Candida sp*.Fungi*Aspergillus, Penicillium, Rhizopus, Mucor, Rhizomucor, Fusarium* and *Curvularia*---have greater invasive potentialVirusHSV, CMVMultiresistant bacteriaMRSA, VRE, MDR *Pseudomonal* and *Acinetobacter* species

In order to provide the thermally injured patient with adequate treatment, it is important to have knowledge of each institution's bacterial flora as they vary with geography and over time \[[@CR000410], [@CR000411]\].

Fungal infections have increased in frequency with the use of topical agents, and the incidence of mycotic invasions has doubled. Even though the burn wound is the most commonly infected site, there is an increasing trend toward systemic and organ-specific fungal infections \[[@CR000412]\].

The diagnosis of fungal infection is complicated by delay in their identification as cultures typically require 7--14 days \[[@CR000413]\], and their clinical presentation is similar to low-grade bacterial infections. Diagnosis can be aided by arterial blood samples as well retinal examination.

### Clinical Management {#Sec00044}

Early excision and wound coverage is the mainstay of modern burn care and best method of minimizing burn wound infection. Any delay in the surgical treatment of burn wounds leads to increased bacterial loads, and any wound with bacterial counts exceeding 10^5^ organisms per gram of tissue can develop burn wound sepsis even after burn wound excision \[[@CR00049]\].

The treatment of burn wound infections involves both local and systemic therapy.

#### Local {#Sec00045}

Early excision of burn eschar (for un-excised burns)Aggressive excision of necrotic/infected tissueTopical agents (Table [4.2](#Tab00042){ref-type="table"}) to minimize bacterial colonization \[[@CR000414]\]Table 4.2Topical agents and the antimicrobial activityAgentAffective againstSilver sulfadiazineGram-positives, gram-negatives, yeastMafenide acetate (5 %)Gram-positives, gram-negativesSilver nitrate (0.5 %)Gram-positives, gram-negatives, yeast, fungiAcetic acid (0.5 %, 2 %)Gram-positives, gram-negatives, pseudomonas at higher concentrationDakin's solution (0.25 % or 0.5 %sodium hypochlorite)Gram-positives, gram-negatives, yeast, fungiActicoatGram-positives, gram-negatives, yeast, fungi, MRSA, VRE

The use of any particular topical agent should be based on suspected organism in the wound but is at times guided by the availability of the agent on hospital formulary. These are not substitute for aggressive surgical management of wound infections.

#### Systemic {#Sec00046}

Use of antibiotics and antifungals should be reserved for patients demonstrating systemic signs of sepsis (see ABA criteria for definition of sepsis (Box [4.1](#Sec00047){ref-type="sec"})).Use of systemic prophylaxis can reduce the rate of surgical wound infections but can increase bacterial antimicrobial resistance \[[@CR000415]\].The choice of antimicrobials needs to be based on each institution's antibiogram and tailored specifically to the organism (Table [4.3](#Tab00043){ref-type="table"}), i.e., narrow the coverage as soon as sensitivities become available.Table 4.3Ross Tilley Burn Centre guidelines for empiric antibiotic therapy*Early phase* (*\<5 days*)The most common pathogens (from any source) in the *early* phase of a patient's admission are:Gram-positive*Staphylococcus aureus* (∼90 % susceptible to cloxacillin)Gram-negatives (95 % susceptibility to ceftriaxone)*H. influenzaE. coliKlebsiella spp*.Based on this data, septic patients admitted within the past 5 days should be started on an empiric regimen of:Ceftriaxone 1 g IV q24 h+/− Cloxacilliin 1--2 g IV q4--6 h (renal dosing required)Penicillin allergyLevofloxacin 750 mg IV/PO q24 h*Late phase* (*\>5 days*)The most common pathogens (from any source) in the *late* phase of a patient's admission are:Gram-positive*Staphylococcus aureus* (only ∼60 % susceptible to cloxacillin)Gram-negative (generally more predominant in the late phase)*Pseudomonas aeruginosa* (\>80 % susceptible to piperacillin/tazobactam)Based on this data, septic patients admitted 5 days or more should be started on an empiric regimen of:Piperacillin/tazobactam 4.5 g IV q6 h (renal dosing required) +  Vancomycin 1 g IV q12 h (with pre- and post-levels around the third dose)OrMeropenem 500 mg IV q6 h (renal dosing required)Yeast species (*Candida*) are typically sensitive to fluconazole, while fungal infections would most likely require treatment with amphotericin or caspofungin (the use is for systemic infection, as wound infections require surgical debridement).Viral infections (typically HSV) require treatment with acyclovir.

Infections of burn wounds are typically found in patients with burns exceeding 20 % TBSA and most commonly in the lower extremities \[[@CR000417]\]. However, there are no specific organisms associated with the site of infection \[[@CR000417]\]. Moreover, these infections can have dire consequences: Conversion of superficial to deeper burn woundsSystemic infection and sepsisGraft loss requiring further surgery for regraftingIncreased hospital length of stayConversion of donor sites requiring surgical debridement and graftingIncreased mortality, more so with yeast and fungal infection

#####  {#Sec00047}

Includes at least three of the following:

Temperature \>39° or \<36.5 °C

Progressive tachycardia Adults \>110 bpmChildren \>2 SD above age-specific norms (85 % age-adjusted max heart rate)

Progressive tachypnea Adults \>25 bpm not ventilated. Minute ventilation \>12 L/min ventilatedChildren \>2 SD above age-specific norms (85 % age-adjusted max respiratory rate)

Thrombocytopenia (will not apply until 3 days after initial resuscitation) Adults \<100,000/mclChildren \>2 SD below age-specific norms

Hyperglycemia (in the absence of preexisting diabetes mellitus) Untreated plasma glucose \>200 mg/dL or equivalent mM/LInsulin resistance---examples include: \>7 units of insulin/h intravenous drip (adults)Significant resistance to insulin (\>25 % increase in insulin requirements over 24 h)

Inability to continue enteral feedings \>24 h Abdominal distensionEnteral feeding intolerance (residual \>150 mL/h in children or two times feeding rate in adults)Uncontrollable diarrhea (\>2,500 mL/day for adults or \>400 mL/day in children)

In addition, it is *required* that a documented infection (defined below) is identified: Culture-positive infectionPathologic tissue source identifiedClinical response to antimicrobials

### Conclusion {#Sec00048}

Burn wound infection is an all too common complication of the thermally injured patient. These infections tend to have a chronological appearance and depend on burn size, depth, length of hospital stay, and geographical location. The common organisms remain *Staphylococcus* and *Pseudomonas*; however, more resistant strains are becoming prevalent. The clinician needs to be vigilant with surveillance of burn wounds and institute aggressive treatment of wound infection once clinical signs appear before systemic illness sets in. It is of utmost importance to have ongoing assessment of the unique flora of each institution in order to better utilize systemic therapy.

Ventilator-Associated Pneumonia {#Sec00049}
===============================

Ventilator-associated pneumonia (VAP) as defined by CDC (Center for Diseases Control) is an infection that occurs in a mechanically ventilated patient with an endotracheal or tracheostomy tube (traditionally \>48 h after hospital admission) \[[@CR000418], [@CR000419]\]. The diagnosis of VAP in the thermally injured patient can be challenging, as fever, leukocytosis, tachycardia, and tachypnea can be present in these patients without infection. The sources of bacteria are typically the oropharynx and upper gastrointestinal tract \[[@CR000420]--[@CR000424]\]. The organisms also have a temporal pattern, community-acquired organisms (*Streptococcus pneumoniae and Haemophilus influenza*) are dominant in the early-phase VAP and Gram-negative and multiresistant organisms (i.e., MRSA) are the common pathogens in late-stage VAP.

Regardless of the organisms, early antimicrobial treatment guided toward the likely organism based on the onset of VAP (early vs. late) is beneficial in the overall outcome of the patients \[[@CR000425]--[@CR000430]\]. These broad-spectrum antimicrobials would need to be de-escalated as culture and sensitivities become available \[[@CR000431]--[@CR000433]\].

As VAP is an increasing common complication with significant consequences, VAP prevention strategies need to be implemented and ABA guidelines (Box [4.2](#Sec000410){ref-type="sec"}) utilized to improve overall patient outcome.

 {#Sec000410}

Mechanically ventilated burn patients are at high risk for developing VAP, with the presence of inhalation injury as a unique risk factor in this patient group.VAP prevention strategies should be used in mechanically ventilated burn patients.Clinical diagnosis of VAP can be challenging in mechanically ventilated burn patients where systemic inflammation and acute lung injury are prevalent. Therefore, a quantitative strategy, when available, is the preferable method to confirm the diagnosis of VAP.An 8-day course of targeted antibiotic therapy is generally sufficient to treat VAP; however, resistant *Staphylococcus aureus* and Gram-negative bacilli may require longer treatment duration.

Central Line-Associated Infections {#Sec000411}
==================================

Central catheters inserted into veins and arteries are common practice in the management of the critically ill thermally injured patient and can be associated with infection rates from 1.5 to 20 % \[[@CR000435]--[@CR000437]\]. The introduction of central line insertion bundles by CDC has dramatically reduced these infections \[[@CR000438], [@CR000439]\]. These measures include: Hand washingFull-barrier precautions during line insertionCleaning the skin with chlorhexidineAvoiding the femoral site if possibleRemoving unnecessary catheters

In burn patients some unique features complicate the use of the central catheters. Typically there are associated burn wounds in close proximity, and it has been shown that catheters within 25 cm^2^ of an open wound are at an increased risk of colonization and infection \[[@CR000440]\]. Other risk factors associated with increased rate of infection are \[[@CR000441]\]: Age (extremes of age have more infection)Sex (female)%TBSA burned% full-thickness burnsPresence of smoke inhalationType of burn (flame)Number of surgical procedures performedLarger number of CVCsLonger insertion of the catheterWound burn infection or colonizationInsertion of the venous catheter in emergency situationLonger stay in hospitalMore operationsInsertion site near the burns wound

The diagnosis of catheter-related infection (CRI) is based on clinical and microbiological criteria (see Table [4.4](#Tab00044){ref-type="table"}). Following the diagnosis of CRI prompt treatment is essential as delay in catheter removal or in the start of appropriate antimicrobial therapy can result in increased morbidity and mortality \[[@CR000443]\].Table 4.4Catheter-related infection \[[@CR000442]\]Type of infectionCriteriaCatheter colonizationA significant growth of a microorganism from the catheter tip, subcutaneous segment, or catheter hub in the absence of clinical signs of infectionExit-site infectionMicrobiologically documented exudates at catheter exit site yield a microorganism with or without concomitant bloodstream infection.Clinically documented erythema or induration within 2 cm of the catheter exit site in the absence of associated bloodstream infection and without concomitant purulencePositive blood cultureMicroorganism, potentially pathogenic, cultured from one or more blood cultureBloodstream infectionPositive blood culture with a clinical sepsis (see below)Clinical sepsisRequires one of the following with no other recognized cause: fever (\>38 °C), hypotension (SBP \<90 mmHg), oliguria, paired quantitative blood cultures with a \>5:1 ratio catheter versus peripheral, differential time to positivity (blood culture obtained from a CVC is positive at least 2 h earlier than a peripheral blood culture)

Currently there is no clear evidence that routine exchange of lines decreases the rate of catheter-related blood stream infections (CRBSI) \[[@CR000444]\]; however, all catheters need to be removed once a CRBSI is diagnosed or once they are no longer needed.

As with all severe infections empiric antimicrobial treatment should be initiated immediately and should take into account the severity of the illness, the site of catheter insertion, and the institutions' antibiogram \[[@CR000445]\]. These broad-spectrum antimicrobials need to be de-escalated after identification and susceptibility testing of the microorganism.

Guidelines for Sepsis Resuscitation {#Sec000412}
===================================

As described in the previous segments of this chapter, infections in the thermally injured patient have dire consequences. Sepsis occurs at a rate of 8--42.5 % in burn patients with a mortality of 28--65 % \[[@CR000446]\]. Much research has been conducted in the optimal management of the septic patient. The following Table [4.5](#Tab00045){ref-type="table"} summarizes the guidelines as recommended by the surviving sepsis campaign committee \[[@CR000447]\]. Only the strong recommendations with high level of evidence are included. This is to be used as a tool to guide the delivery of optimal clinical care for patients with sepsis and septic shock. The ABA criteria for definition of sepsis (see Box [4.1](#Sec00047){ref-type="sec"}) in the burn patients have been established. However, Mann-Salinas and colleagues have challenged the predictive ability of ABA criteria demonstrating that their multivariable model (heart rate \>130, MAP \<60 mmHg, base deficit \<  −6 mEq/L, temperature \<36 °C, use of vasoactive medications, and glucose \>150 mg/dL) is capable of outperforming the ABA model \[[@CR000448]\].Table 4.5Guidelines for management of sepsis and septic shock \[[@CR000447]\]^a^Initial resuscitation (first 6 h)Begin resuscitation immediately in patients with hypotension or elevated serum lactate \>4 mmol/L; do not delay pending ICU admissionResuscitation goals:CVP 8--12 mmHgMean arterial pressure ≥65 mmHgUrine output ≥0.5 mL/kg/hCentral venous (superior vena cava) oxygen saturation ≥70 % or mixed venous ≥65 %DiagnosisObtain appropriate cultures before starting antibiotics provided this does not significantly delay antimicrobial administrationObtain two or more BCsOne or more BCs should be percutaneousOne BC from each vascular access device in place \>48 hCulture other sites as clinically indicatedPerform imaging studies promptly to confirm and sample any source of infection, if safe to do soAntibiotic therapyBegin intravenous antibiotics as early as possible and always within the first hour of recognizing severe sepsis and septic shockBroad-spectrum: one or more agents active against likely bacterial/fungal pathogens and with good penetration into presumed sourceReassess antimicrobial regimen daily to optimize efficacy, prevent resistance, avoid toxicity, and minimize costsConsider combination therapy in Pseudomonas infectionsConsider combination empiric therapy in neutropenic patientsCombination therapy ≤3--5 days and de-escalation following susceptibilitiesDuration of therapy typically limited to 7--10 days; longer if response is slow or there are undrainable foci of infection or immunologic deficienciesStop antimicrobial therapy if cause is found to be noninfectiousSource identification and controlA specific anatomic site of infection should be established as rapidly as possible and within first 6 h of presentationFormally evaluate patient for a focus of infection amenable to source control measures (e.g., abscess drainage, tissue debridement)Implement source control measures as soon as possible following successful initial resuscitation (exception: infected pancreatic necrosis, where surgical intervention is best delayed)Choose source control measure with maximum efficacy and minimal physiologic upset. Remove intravascular access devices if potentially infectedFluid therapyFluid-resuscitate using crystalloids or colloidsTarget a CVP of ≥8 mmHg (≥12 mmHg if mechanically ventilated)Use a fluid challenge technique while associated with a hemodynamic improvementGive fluid challenges of 1,000 mL of crystalloids or 300--500 mL of colloids over 30 min. More rapid and larger volumes may be required in sepsis-induced tissue hypoperfusionRate of fluid administration should be reduced if cardiac filling pressures increase without concurrent hemodynamic improvementVasopressorsMaintain MAP ≥65 mmHgNorepinephrine and dopamine centrally administered are the initial vasopressors of choiceDo not use low-dose dopamine for renal protectionIn patients requiring vasopressors, insert an arterial catheter as soon as practicalInotropic therapyUse dobutamine in patients with myocardial dysfunction as supported by elevated cardiac filling pressures and low cardiac outputDo not increase cardiac index to predetermined supernormal levelsSteroidsDo not use corticosteroids to treat sepsis in the absence of shock unless the patient's endocrine or corticosteroid history warrants itRecombinant human activated protein CAdult patients with severe sepsis and low risk of death (typically, APACHE II \<20 or one organ failure) should not receive rhAPCBlood product administrationGive red blood cells when hemoglobin decreases to \<7.0 g/dL (\<70 g/L) to target hemoglobin of 7.0--9.0 g/dL in adults. A higher hemoglobin level may be required in special circumstances (e.g., myocardial ischemia, severe hypoxemia, acute hemorrhage, cyanotic heart disease, or lactic acidosis)Do not use antithrombin therapyMechanical ventilation of sepsis-inducedALI/ARDSTarget a tidal volume of 6 mL/kg (predicted) body weight in patients with ALI/ARDSTarget an initial upper limit plateau pressure ≤30 cm H~2~O. Consider chest wall compliance when assessing plateau pressureAllow PaCO~2~ to increase above normal, if needed, to minimize plateau pressures and tidal volumesSet PEEP to avoid extensive lung collapse at end expirationMaintain mechanically ventilated patients in a semi-recumbent position (head of the bed raised to 45°) unless contraindicatedUse a weaning protocol and an SBT regularly to evaluate the potential for discontinuing mechanical ventilationSBT options include a low level of pressure support with continuous positive airway pressure 5 cm H~2~O or a T pieceDo not use a pulmonary artery catheter for the routine monitoring of patients with ALI/ARDSUse a conservative fluid strategy for patients with established ALI who do not have evidence of tissue hypoperfusionSedation, analgesia, and neuromuscular blockade in sepsisUse sedation protocols with a sedation goal for critically ill mechanically ventilated patientsUse either intermittent bolus sedation or continuous infusion sedation to predetermined end points (sedation scales), with daily interruption/lightening to produce awakeningAvoid neuromuscular blockers where possible. Monitor depth of block with train-of-four when using continuous infusionsGlucose controlUse intravenous insulin to control hyperglycemia in patients with severe sepsis following stabilization in the ICUAim to keep blood glucose \<150 mg/dL (8.3 mmol/L) using a validated protocol for insulin dose adjustmentProvide a glucose calorie source and monitor blood glucose values every 1--2 h (4 h when stable) in patients receiving intravenous insulinInterpret with caution low glucose levels obtained with point of care testing, as these techniques may overestimate arterial blood or plasma glucose valuesBicarbonate therapyDo not use bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements when treating hypoperfusion-induced lactic acidemia with pH ≥7.15DVT prophylaxisUse a mechanical prophylactic device, such as compression stockings or an intermittent compression device, when heparin is contraindicatedUse either low-dose UFH or LMWH, unless contraindicatedStress ulcer prophylaxisProvide stress ulcer prophylaxis using H2 blocker or proton pump inhibitorConsideration for limitation of supportDiscuss advance care planning with patients and families. Describe likely outcomes and set realistic expectations^a^Adapted from Dellinger et al. \[[@CR000447]\]
